ReviewJournal of immunology (Baltimore, Md. : 1950)2024
The Lung Microbiome.
Review in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Association between OLD and IBD: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Composition and diversity of the pulmonary microbiome in acute respiratory distress syndrome: a systematic review.Critical care (London, England) · 2025Pooled it
- Airway microbial compartmentalization under mechanical ventilation: a randomized pilot study comparing an endotracheal tube with suction and continuous cuff pressure control (Venner PneuXRespiratory research · 2026Trial
- Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Mitochondria Meet the Lung Microbiome: A Bidirectional Dialogue in Inflammation and Respiratory Diseases.Biomedicines · 2026Review
- The Impact of Plant-Derived Foods and Medicines on the Lung-Gut Axis and Microbiota Cross-Talk.Molecules (Basel, Switzerland) · 2026Review
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Modulator therapy: rates and stages of respiratory bacteriome restoration in cystic fibrosis patients chronically infected with Pseudomonadota.BMC pulmonary medicine · 2026Article
- Lung microbiota analysis in early-stage lung adenocarcinoma.Microbiology spectrum · 2026Article
- Salivary microbiota composition and caries status in children with hearing impairment: a cross-sectional comparative study.Clinical oral investigations · 2026Article
- Indole-acetaldehyde from Rothia mucilaginosa activates the PXR/NRF2 axis to enhance alveolar macrophage phagocytosis and protect against ARDS.Respiratory research · 2026Article
- Progressive microbial alterations in the human gut and lung across early life: implications for translational medicine.Frontiers in cellular and infection microbiology · 2026Review
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
- [Research Progress on the Regulatory Mechanism of Respiratory Microbiota in the Comorbidity of Chronic Obstructive Pulmonary Disease and Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Early-life viral infections and asthma: new cells and ideas.Current opinion in pediatrics · 2025Review
- Extensive diversity of unusual microorganisms associated with severe pneumonia in kidney transplant recipients.PLoS pathogens · 2025Article
- CombinedInternational journal of molecular sciences · 2025Article
- The Respiratory Tract Microbiome and Human Health.Microbial biotechnology · 2025Review
- The lung microbiome in interstitial lung disease.Breathe (Sheffield, England) · 2025Review
- Multiomics as instrument to promote 3P medical approaches for the overall management of respiratory syncytial viral infections.The EPMA journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Although the lungs were once considered a sterile environment, advances in sequencing technology have revealed dynamic, low-biomass communities in the respiratory tract, even in health. Key features of these communities-composition, diversity, and burden-are consistently altered in lung disease, associate with host physiology and immunity, and can predict clinical outcomes. Although initial studies of the lung microbiome were descriptive, recent studies have leveraged advances in technology to identify metabolically active microbes and potential associations with their immunomodulatory by-products and lung disease. In this brief review, we discuss novel insights in airway disease and parenchymal lung disease, exploring host-microbiome interactions in disease pathogenesis. We also discuss complex interactions between gut and oropharyngeal microbiota and lung immunobiology. Our advancing knowledge of the lung microbiome will provide disease targets in acute and chronic lung disease and may facilitate the development of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.